Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy

NCT01826474 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT01826474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01826474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2013
Completion date
August 31, 2016
Enrollment
15 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy